Background: In vivo imaging using genetic reporters is a central supporting tool in the development of cell and gene therapies affording us the ability to selectively track the therapeutic indefinitely. Previous studies have demonstrated the utility of the human norepinephrine transporter (hNET) as a positron emission tomography/single photon emission computed tomography (PET/SPECT) genetic reporter for in vivo cellular imaging. Here, our aim was to extend on this work and construct a tricistronic vector with dual optical (firefly luciferase) and nuclear (hNET) in vivo imaging and ex vivo histochemical capabilities. Guiding this development, we describe how a fluorescent substrate for hNET, 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP + ), can be used to optimise vector design and serve as an in vitro functional screen. Methods: Vectors were designed to co-express a bright red-shifted firefly luciferase (FLuc), hNET and a small marker gene RQR8. Genes were co-expressed using 2A peptide linkage, and vectors were transduced into a T cell line, SupT1. Two vectors were constructed with different gene orientations; FLuc.2A.RQR8.2A.hNET and hNET.2A.FLuc.2A. RQR8. hNET function was assessed using ASP + -guided flow cytometry. In vivo cellular conspicuity was confirmed using sequential bioluminescence imaging (BLI) and SPECT imaging of transduced SupT1 cells injected into the flanks of mice. Results: SupT1/FLuc.2A.RQR8.2A.hNET cells resulted in >4-fold higher ASP + uptake compared to SupT1/hNET.2A. FLuc.2A.RQR8, suggesting that 2A orientation effected hNET function. SupT1/FLuc.2A.RQR8.2A.hNET cells were readily visualised with both BLI and SPECT, demonstrating high signal to noise at 24 h post
Background
Cellular therapy with engineered cells is a promising area and is finding increasing application in regenerative medicine and cancer adoptive immunotherapy. In the clinical setting, T cell-based studies using chimeric antigen receptor (CAR) therapy have shown outstanding efficacy in refractory cancers [1] [2] [3] [4] . More broadly, induced progenitor cells have been shown to regenerate different organs and systems in neurodegenerative [5] , cardiovascular [6, 7] and musculoskeletal [8] disorders. These therapeutics are different from standard therapies such as small molecules or proteins: they are essentially living therapies with no half-life, a complex engraftment and multifaceted in vivo behaviour.
A key limitation of pre-clinical and clinical development of advanced cellular therapies is lack of a satisfactory method for tracking these cells over sufficiently long periods of time. Direct or transient labelling methods, such as iron-labelled cells for magnetic resonance imaging (MRI) or 111 In-oxine-labelled cells for single photon emission computed tomography (SPECT) are unsuitable for the time frame of immunotherapy studies. These allow imaging over hours/days [9] [10] [11] [12] [13] [14] , which are insufficient to study the complex biological integration and efficacy of cellular therapies, which can evolve over many weeks and months. A credible option is selective genetic modification of cells with a marker gene, using an integrating vector, to selectively track the cellular therapeutic indefinitely. Several different approaches to genetic reporter imaging have been proposed [15, 16] . As a translational approach, positron emission tomography (PET) or SPECT show most promise. One such PET/SPECT genetic reporter is the human norepinephrine transporter (hNET) [17] . In combination with radiolabelled noradrenaline analogues, meta-iodobenzylguanidine (MIBG) or metahydroxyephedrine (mHED), hNET engineered cells can be mapped in vivo via SPECT ( C-mHED) [17] [18] [19] . It has been demonstrated that the technique has quantitative capabilities and has been used in longitudinal imaging studies of adoptively transferred T cells and gene therapy [20, 21] .
Here our aim was to construct a tricistronic vector coexpressing hNET with firefly luciferase (FLuc) and a compact suicide/marker gene, RQR8 [22] . This triple construct extends upon the previously designed hNETeGFP bicistronic construct [18] . The hNET-FLuc construct is a novel addition for in vivo bioluminescence imaging (BLI), and the triple construct of hNET-FLuc-RQR8 has potential for histochemistry and therapeutic application. In this study, several vector constructs were designed and tested. Screening for a lead construct, we show that hNET function can be assessed in vitro using ASP + , a fluorescent analogue of the neurotoxin MPP + and hNET substrate [23, 24] Optimal ASP + staining conditions determined above were used for ASP + -guided flow sorting of SupT1 cell lines expressing the three hNET vector constructs. Cells were prepared as described above. ASP + mean fluorescence intensities (MFI) were determined preand post-FACS (Beckman Coulter MoFlo-XDP) using areas under the curve and subtracting any non-specific signal from non-transduced SupT1 (SupT1/NT) cell populations. Measurements were acquired in triplicates for each cell line and statistical significance of differences between mean values was obtained with IBM SPSS software using the one-way ANOVA and the Tukey's HSD test.
In vitro radiotracer uptake assay 125 I]-MIBG cell uptake was calculated by dividing the counts in the cell pellet by the total counts (counts in cell pellet + counts in supernatant). All experiments were performed in triplicates. The one-way ANOVA and the Tukey's HSD test were used to determine the significance of differences between mean values.
In vivo bioluminescence and SPECT/CT imaging
All animal procedures were carried out in accordance with the UK Animals (Scientific Procedures) 1986 Act and institutional ethics regulation. SupT1/FLuc.2A. RQR8.2A.hNET cells (5 × 10 6 ) or non-transduced SupT1 cells (5 × 10 6 ) were injected into the subcutaneous space of the right flank of NOD/SCID mice (n = 3 in each group). Seven days later, BLI images (Biospace photon imager Optima system, Paris, France) were acquired 15 min post-intraperitoneal administration of 200 μL of DLuciferin (10 mg/mL) using a 50 mm CCD lens with a sensitivity of 37 photons/s/sr/cm 2 . Images were analysed using Biospace M3 Vision software. 15 MBq (150 μL) of [ 123 I]-MIBG (Mallinckrodt, Northampton, UK) was subsequently administered to animals via tail vein followed by whole body SPECT/CT imaging (nanoSPECT silver upgrade, Mediso, Budapest, Hungary) at 1 h, 4 h and 24 h post injection. Images were reconstructed using HiS-PECT software (InviCRO, Boston, USA) followed by image processing and analysis using VivoQuant Software (InviCRO, Boston, USA). Functional determination of hNET vectors requires costly and complex radiochemistry work. We hypothesised that the fluorescent NET substrate ASP + could allow determination of hNET function based on flow cytometry. A concentration and time-course titration assay was designed to determine optimised conditions for efficient cell staining and sorting of hNET expressing cells using ASP + . hNET expressing and non-transduced SupT1 cells were compared to quantify non-specific uptake ( Figure 1 ). Adequate discrimination between specific and non-specific ASP + staining is essential to study efficiency of hNET encoding vector transduction and reporter function and to facilitate isolation of pure hNET positive cell populations. We determined that ASP + is both specifically and non-specifically taken up by cells (Figure 1 ). We observed good discrimination of specific and non-specific staining with a two-log shift in fluorescence. Optimal separation between hNET positive and hNET negative cells, using minimum incubation time and ASP + concentration, was 30 min and 0.05 μM ASP + ( Figure 1 ).
Results

ASP
Tricistronic pre-clinical vector for histochemistry, BLI and SPECT tracking of engineered cells
We constructed a tricistronic vector which allows engineered cells to be tracked in vivo by BLI and SPECT/ PET and ex vivo by histochemistry. We co-expressed a bright red-shifted firefly luciferase, along with the hNET and RQR8 -a small marker gene which binds the widely used antibody QBEnd/10 enabling flow cytometry and histochemistry. We used 2A peptide linkage to drive obligate stoichiometric co-expression [26] . Two candidate tricistronic vector constructs were designed and tested; one with 2A peptide linkage at the N-terminus of hNET (FLuc.2A.RQR8.2A.hNET) and one at the C-terminus (hNET.2A.FLuc.2A.RQR8). RQR8 function and transduction efficiency of the two vectors was verified via flow cytometry and QBEnd10 staining. As a reference, SupT1 cells encoding an IRES linked bicistronic vector (SupT1/hNET.I.CD34) were used. Using the optimal staining conditions determined above, ASP + -guided FACS was performed to isolate hNET positive SupT1 cells by gating on the brightest 5% of each population. Post sorting, positive ASP + staining increased from 59.4% to 99% ± 0.01% for SupT1/hNET.l.dCD34, 46.2% to 93.6% ± 0.34% for SupT1/FLuc.2A.RQR8.2A.hNET, and 52.4% to 93.6% ± 0.66% for SupT1/hNET.2A. Table S1 ). earlier reports suggesting a late imaging paradigm is favourable when imaging hNET cells with MIBG [21] , good signal-to-noise was observed at 24 h post radiotracer administration (Figure 4d,e) . At the earlier time points of 30 min and 4 h, renal clearance is observed with high signal in the kidneys and bladder, with increasing signal in the adrenals (high NET expressing organ) (Figure 4b,c) . Increasing signal was also observed in the salivary and thyroid glands (sodium iodide symporter expressing organs) due to tracer metabolism/ deiodination (Figure 4b,c,d ,e). With decreased background signal at 24 h, radiotracer accumulation in the subcutaneous tumour can clearly be seen with regional heterogeneity resolved. Percent injected dose (% ID) of 123 I-MIBG in tumours at 24 h post injection, as determined by drawing image-guided 3D regions of interest, was 3.12% ± 0.31% ID in hNET(+) xenografts, and 0.019% ± 0.01% ID in hNET(−) xenografts (equivalent to background levels).
Discussion
With the development of new cellular and gene therapies, there is a need for non-invasive, readily available methods for detecting and quantifying the fate of these therapies in animal and man. As a translational approach, PET and SPECT genetic reporters have shown promise and have supported numerous clinical trials [27] [28] [29] . Various PET/SPECT reporter proteins have been proposed including the human sodium iodide symporter (hNIS), the hNET and the herpes simplex virus thymidine kinase (HSVtk) [16, 17, 30, 31] . Difficulties in translating these into clinic include availability of clinically approved complementary radiotracers, early planning necessary to integrate the reporter protein and imaging protocol into trial design, incorporation of the reporter gene into the vector without exceeding the packaging capacity or affecting cell function and limited sensitivity in tissues with endogenous expression of the reporter protein. In preclinical imaging, taking advantage of the strengths each modality (e.g. MRI, optical and nuclear) has to offer, the use of multimodal multicistronic reporters is becoming increasingly popular [16] . For example, co-expression of PET and BLI reporters would enable rapid, affordable and sensitive BLI, alongside complementary tomographic and quantitative PET capabilities. Expression vectors are often composed of multiple genes (e.g. a therapeutic, a marker gene, a suicide gene and a reporter gene) some of which can be large surface proteins, which may tax the vector packaging capacity and transcriptional efficiency. Strategies which promote maximising vector space are therefore essential and may include gene and protein truncation [22, 32] , efficient gene coupling approaches [33, 34] and the utility of dual purpose genes [22, 35, 36] .
Here, we have developed a trisictronic expression vector containing a nuclear reporter (hNET), a BLI reporter (FLuc) and a highly compact dual-purpose marker/suicide gene (RQR8). To achieve a compact vector, genes were linked with the 'self-cleaving' small 2A peptide, driving obligate co-expression under a single promoter (26) . Exploiting the endogenous fluorescent properties of the hNET substrate ASP + , it was possible to simultaneously, and efficiently, sort pure cell populations and evaluate reporter function. Such a system is unique to hNET as a nuclear reporter and may circumvent the need for in vitro radioligand cell uptake assays prior to in vivo use. Furthermore, as hNET positive cells can be efficiently sorted using ASP + -guided flow cytometry, hNET could double up as a marker gene, leaving more flexibility to insert other genes in the expression vector.
Using ASP + -guided flow cytometry, we demonstrated that residual 2A amino acids attached to the C-terminus of the transcribed hNET markedly reduced the protein capacity to accumulate substrate into the cell. This finding further corroborates previous structure/function studies indicating the critical contribution of the hNET C-terminus to transporter trafficking, stability and function [37, 38] . Consequently, an expression vector with 2A cleavage site upstream of hNET was taken forward for in vivo assessment. FLuc/hNET cells were successfully visualised using sequential BLI and SPECT imaging demonstrating high target to background tumour visualisation at 24 h post 123 I-MIBG administration. 
